How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion

• A correct patient risk stratification is of paramount importance for the proper management of economic and human resources. • Clinical trials are crucial to assessing immunosuppressant prophylaxis and treatment to avoid overuse and treatment shortage. • Controlled studies may highlight a potential...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarzi-Puttini, Piercarlo, Marotto, Daniela, Antivalle, Marco, Salaffi, Fausto, Atzeni, Fabiola, Maconi, Giovanni, Monteleone, Giovanni, Rizzardini, Giuliano, Antinori, Spinello, Galli, Massimo, Ardizzone, Sandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200131/
https://www.ncbi.nlm.nih.gov/pubmed/32376399
http://dx.doi.org/10.1016/j.autrev.2020.102574
_version_ 1783529275663581184
author Sarzi-Puttini, Piercarlo
Marotto, Daniela
Antivalle, Marco
Salaffi, Fausto
Atzeni, Fabiola
Maconi, Giovanni
Monteleone, Giovanni
Rizzardini, Giuliano
Antinori, Spinello
Galli, Massimo
Ardizzone, Sandro
author_facet Sarzi-Puttini, Piercarlo
Marotto, Daniela
Antivalle, Marco
Salaffi, Fausto
Atzeni, Fabiola
Maconi, Giovanni
Monteleone, Giovanni
Rizzardini, Giuliano
Antinori, Spinello
Galli, Massimo
Ardizzone, Sandro
author_sort Sarzi-Puttini, Piercarlo
collection PubMed
description • A correct patient risk stratification is of paramount importance for the proper management of economic and human resources. • Clinical trials are crucial to assessing immunosuppressant prophylaxis and treatment to avoid overuse and treatment shortage. • Controlled studies may highlight a potential preventive role of immunosuppressant in the development of Covid-19 severe forms; • Despite the risk of infection in rheumatic and gastroenterological diseases a conclusive link with COV-19 remains questionable.
format Online
Article
Text
id pubmed-7200131
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-72001312020-05-06 How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion Sarzi-Puttini, Piercarlo Marotto, Daniela Antivalle, Marco Salaffi, Fausto Atzeni, Fabiola Maconi, Giovanni Monteleone, Giovanni Rizzardini, Giuliano Antinori, Spinello Galli, Massimo Ardizzone, Sandro Autoimmun Rev Article • A correct patient risk stratification is of paramount importance for the proper management of economic and human resources. • Clinical trials are crucial to assessing immunosuppressant prophylaxis and treatment to avoid overuse and treatment shortage. • Controlled studies may highlight a potential preventive role of immunosuppressant in the development of Covid-19 severe forms; • Despite the risk of infection in rheumatic and gastroenterological diseases a conclusive link with COV-19 remains questionable. Published by Elsevier B.V. 2020-07 2020-05-05 /pmc/articles/PMC7200131/ /pubmed/32376399 http://dx.doi.org/10.1016/j.autrev.2020.102574 Text en © 2020 Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Sarzi-Puttini, Piercarlo
Marotto, Daniela
Antivalle, Marco
Salaffi, Fausto
Atzeni, Fabiola
Maconi, Giovanni
Monteleone, Giovanni
Rizzardini, Giuliano
Antinori, Spinello
Galli, Massimo
Ardizzone, Sandro
How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion
title How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion
title_full How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion
title_fullStr How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion
title_full_unstemmed How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion
title_short How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion
title_sort how to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the covid-19 era: an expert opinion
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200131/
https://www.ncbi.nlm.nih.gov/pubmed/32376399
http://dx.doi.org/10.1016/j.autrev.2020.102574
work_keys_str_mv AT sarziputtinipiercarlo howtohandlepatientswithautoimmunerheumaticandinflammatoryboweldiseasesinthecovid19eraanexpertopinion
AT marottodaniela howtohandlepatientswithautoimmunerheumaticandinflammatoryboweldiseasesinthecovid19eraanexpertopinion
AT antivallemarco howtohandlepatientswithautoimmunerheumaticandinflammatoryboweldiseasesinthecovid19eraanexpertopinion
AT salaffifausto howtohandlepatientswithautoimmunerheumaticandinflammatoryboweldiseasesinthecovid19eraanexpertopinion
AT atzenifabiola howtohandlepatientswithautoimmunerheumaticandinflammatoryboweldiseasesinthecovid19eraanexpertopinion
AT maconigiovanni howtohandlepatientswithautoimmunerheumaticandinflammatoryboweldiseasesinthecovid19eraanexpertopinion
AT monteleonegiovanni howtohandlepatientswithautoimmunerheumaticandinflammatoryboweldiseasesinthecovid19eraanexpertopinion
AT rizzardinigiuliano howtohandlepatientswithautoimmunerheumaticandinflammatoryboweldiseasesinthecovid19eraanexpertopinion
AT antinorispinello howtohandlepatientswithautoimmunerheumaticandinflammatoryboweldiseasesinthecovid19eraanexpertopinion
AT gallimassimo howtohandlepatientswithautoimmunerheumaticandinflammatoryboweldiseasesinthecovid19eraanexpertopinion
AT ardizzonesandro howtohandlepatientswithautoimmunerheumaticandinflammatoryboweldiseasesinthecovid19eraanexpertopinion

Ejemplares similares